ReviewBreast cancer research : BCR2003
The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer.
Review in Breast cancer research : BCR, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Antagonism of epidermal growth factor receptor signaling favors hepatitis E virus life cycle.Journal of virology · 2024Article
- HER3-targeted therapy: the mechanism of drug resistance and the development of anticancer drugs.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma.Cell death & disease · 2020Article
- Expression and association of IL-21, FBXL20 and tumour suppressor gene PTEN in laryngeal cancer.Saudi journal of biological sciences · 2019Article
- Correlation between PTEN and P62 gene expression in rat colorectal cancer cell.Saudi journal of biological sciences · 2019Article
- Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation.International journal of molecular sciences · 2019Article
- Parkin facilitates proteasome inhibitor-induced apoptosis via suppression of NF-κB activity in hepatocellular carcinoma.Cell death & disease · 2019Article
- Genetic and molecular biology of breast cancer among Iranian patients.Journal of translational medicine · 2019Review
- Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.BMC cancer · 2018Article
- RNF144A sustains EGFR signaling to promote EGF-dependent cell proliferation.The Journal of biological chemistry · 2018Article
- CSN6 controls the proliferation and metastasis of glioblastoma by CHIP-mediated degradation of EGFR.Oncogene · 2017Article
- Real-time imaging of sodium glucose transporter (SGLT1) trafficking and activity in single cells.Physiological reports · 2017Article
- The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.Oncotarget · 2016Article
- Hinokitiol inhibits vasculogenic mimicry activity of breast cancer stem/progenitor cells through proteasome-mediated degradation of epidermal growth factor receptor.Oncology letters · 2016Article
- Excretory/secretory products of the carcinogenic liver fluke are endocytosed by human cholangiocytes and drive cell proliferation and IL6 production.International journal for parasitology · 2015Article
- Article
- E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis.Cell death & disease · 2013Review
- Article
- Differential proteomic analysis of pathway biomarkers in human breast cancer by integrated bioinformatics.Oncology letters · 2012Article
- Expression of the novel human gene, UBE2Q1, in breast tumors.Molecular biology reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Aberrant activity of growth factor receptors has been implicated in the pathogenesis of a wide variety of malignancies. The negative regulation of signaling by growth factor receptors is mediated in large part by the ubiquitination, internalization, and degradation of the activated receptor. Over the past few years, considerable insight into the mechanisms that control receptor downregulation has been gained. There are also data suggesting that mutations that lead to inhibition of downregulation of growth factor receptors could play a role in the pathogenesis of cancer. Therapies directed at enhancing the degradation of growth factor receptors offer a promising approach to the treatment of malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.